Kyowa Hakko Kogyo Co., Ltd.

Abbott Laboratories Corporation

Kyowa Hakko Kogyo Kabushiki Kaisha

Kyowa Hakko Kabushiki Kaisha

Kyowa Hakko Rogyo Kabushiki Kaisha

Isao Kawamoto

Hiroshi Sano

Hiroshi Kase

Katsuhiko Ando

Ryo Okachi

Toru Yasuzawa

Koji Yamada

Takashi Nara

Hirofumi Nakano

Yuzuru Matsuda

Tomoyasu Sato

Mayumi Yoshida

Satoshi Nakanishi

Mitsuyoshi Yamamoto

Seigo Takasawa

Joji Goto

Shigeto Kitamura

Yoshikazu Morishita

Seiji Sato

Kenji Shibata

Motoo Yamasaki

Makoto Morimoto

Keiichi Yano

Masaji Kasai

Kunikatsu Shirahata

Kazuo Yamaguchi

Eiji Tsukuda

Toshiyuki Suzawa

Fusao Tomita

Shigeru Chiba

Isami Takahashi

Kiyoshi Nakayama

Mitsunobu Hara

Takeo Tanaka

Kozo Asano

Noriaki Hirayama

Tatsuhiro Ogawa

Toshihide Ikemura

Atsuko Morikawa

Etsuyo Shimizu

Chieko Bando

Mika Makino

Yutaka Saito

Mitsuru Takahashi

Akio Ozaki

Keiko Ochiai

Eiji Kobayashi

Katsuichi Shuto

Tetsuo Oka

Keiichi Takahashi

Yukio Hashimoto

Hideki Kawasaki

Kazuhisa Fujimoto

Tohru Yasuzawa

Kazutoshi Kuroda

Keishiro Tamura

Makoto Suzuki

Yoshinori Yamashita

Shinichi Hashimoto

Chikara Murakata

Ryoichi Katsumata

Hiromitsu Saito

Akira Karasawa

Kazuhiro Kubo

Tadashi Ashizawa

Katsushige Gomi

Hajime Yoshida

Tatsuya Tamaoki

Shizuo Shiozaki

Takao Iida

Hiroshi Hagino

Junichi Ikeda

Tsuyoshi Mokudai

Hisayo Nomoto

Michio Ichimura

Mika Nozawa

Shinichiro Toki

Keiko Ohsawa

Katsuichi Shutoh

Toshiro Koguchi

Takashi Deguchi

Masayuki Yamato

Kozo Asasno

Tomoyuki Sano

Keiiechi Takahashi

Yohichi Uosaki

Endothelin-antagonizing peptide

The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Strains of streptomyces producing endothelin antagonistic peptides

Peptides represented by the following formula (I): ##STR1## wherein A represents Asn or Asp; B represents His or Lys; and E represents Ala or Ser;

A process for producing L-alanine, which comprises culturing in a medium a microorganism belonging to the genus Arthrobacter which has L-alanine dehydrogenase activity, but little or no alanine racemase activity, and which is capable of producing L-alanine; allowing L-alanine to accumulate in the culture; and recovering L-alanine from the culture.

Process for producing L-alanine by fermentation with arthrobacter

A novel D-amidase is described. The enzyme specifically hydrolyzes D-.alpha.-alanineamide into D-.alpha.-alanine. It is produced by culturing a microorganism belonging to the genus Arthrobacter, and is useful as an enzyme for efficiently producing D-.alpha.-alanine having a high optical purity and/or L-.alpha.-alanineamide from DL-.alpha.-alanineamide or D-.alpha.-alanineamide at low cost.

D-amidase and process for producing D-.alpha.-alanine and/or

KS-506a, KS-506x and KS-506g having an activity to inhibit cyclic nucleotide phosphodiesterase and KS-506m and KS-506h having an activity to inhibit histamine release are produced by culturing a microorganism belonging to the genus Mortierella.

KS-506 compounds

2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds

Compounds comprising a linear .beta.1.fwdarw.6 glucan esterified by caproic acid, the number of D-glucose residues being from 7 to 40 and the number of caproic acid residues being from 2 to 30, may be be obtained by fermentation of a microorganism of the genus Aureobasidium. These compounds are designated HS-142-1. Preferred microorganism is Aureobasidium pullulans var. melanigenum KAC-2383 (FERM-BP 2407). The compounds of the present invention exhibit excellent antagonistic activity to ANP and are capable of inhibiting the bonding of ANP to ANP receptors.

HS-142-1 compounds

Process for producing D-alpha-alanine and/or L-alpha-alanineamide by

A novel fermentation product, DC113, represented by the formula ##STR1## which has antimicrobial and antitumor activities.

Novel substance DC 113 and production thereof

The present invention relates to a compound designated 'DC114-C' having excellent anti-bacterial and anti-tumor activities. This compound may be obtained by fermentation of a microorganism of the genus Streptomyces, preferably Streptomyces sp. DO-114 (FERM BP-2641).

Chemical compound

A compound of formula (I): ##STR1## wherein R.sub.1 represents hydrogen, hydroxy or acetoxy and R.sub.2 represents hydroxy or acetoxy.

Bioxanthracene derivatives

A new compound designated KS-505 having amnesia-inhibiting activity may be prepared by fermentation of a suitable strain of Streptomyces, preferably Streptomyces argenteolus A-2 (FERM BP-2065). The compound is thought to have the structure: ##STR1##

Compound KS-505 useful for improving cerebral function

Disclosed are DC115A compounds represented by the following general formula: ##STR1## wherein R represents ethyl, propyl or 1-propenyl, and which have antibacterial and anti-tumor activity. DC115A compounds are produced by culturing a microorganism belonging to the genus Streptomyces.

DC115A compounds produced by streptomyces sp.

A hydroxamic acid compound represented by the general formula (I) or a salt thereof; ##STR1## wherein R.sup.1 represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R.sup.2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.

Hydroxamic acid derivatives and use thereof in combatting

Growing community of inventors

Hiratsuka, Japan

Isao Kawamoto